
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1.210 | 1.940 | 0.730 |
Stocks | 98.650 | 98.650 | 0.000 |
Bonds | 0.130 | 0.130 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 17.610 | 17.849 |
Price to Book | 3.380 | 3.663 |
Price to Sales | 7.371 | 5.358 |
Price to Cash Flow | 15.838 | 13.587 |
Dividend Yield | 0.159 | 0.512 |
5 Years Earnings Growth | 9.463 | 19.416 |
Number of long holdings: 70
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
argenx ADR | US04016X1019 | 5.78 | 622.61 | -0.33% | |
Insmed | US4576693075 | 4.73 | 76.29 | -6.45% | |
Gilead | US3755581036 | 4.64 | 115.99 | +1.47% | |
Sarepta | US8036071004 | 3.68 | 101.22 | -5.18% | |
Blueprint Medicines Corp | US09627Y1091 | 3.30 | 89.75 | -7.06% | |
Vaxcyte | US92243G1085 | 3.24 | 72.10 | -1.26% | |
Alnylam | US02043Q1076 | 3.16 | 243.53 | -1.31% | |
Regeneron Pharma | US75886F1075 | 3.01 | 684.87 | -1.99% | |
TG | US88322Q1085 | 2.95 | 34.42 | +14.39% | |
Cytokinetics Inc | US23282W6057 | 2.68 | 42.89 | -6.76% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet Global Megatrend Selection P | 11.48B | 5.35 | 4.20 | 7.13 | ||
PIMegatrend Selection I USD | 11.48B | 5.43 | 5.13 | 8.05 | ||
PIMegatrend Selection P dy USD | 11.48B | 5.35 | 4.20 | 7.13 | ||
PIMegatrend Selection R USD | 11.48B | 5.27 | 3.26 | 6.17 | ||
PIMegatrend Selection Z USD | 11.48B | 5.52 | 6.18 | 9.13 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review